SWIG
LCTX icon

Strategic Wealth Investment Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Strategic Wealth Investment Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31,530
Closed -$47.3K – 134
2023
Q1 		$47.3K Hold
31,530
– – 0.01% 129
2022
Q4 		$45.7K Sell
31,530
-5,478
-15% -$6.9K 0.01% 119
2022
Q3 		$42K Sell
37,008
-12,728
-26% -$18.7K 0.01% 110
2022
Q2 		$79K Sell
49,736
-12,752
-20% -$16.8K 0.02% 130
2022
Q1 		$96K Sell
62,488
-2,581
-4% -$4K 0.02% 99
2021
Q4 		$159K Sell
65,069
-5,556
-8% -$13K 0.04% 84
2021
Q3 		$179K Buy
70,625
+6,393
+10% +$16.4K 0.05% 81
2021
Q2 		$183K Sell
64,232
-382
-0.6% -$988 0.06% 82
2021
Q1 		$152K Sell
64,614
-2,303
-3% -$5.53K 0.07% 72
2020
Q4 		$118K Sell
66,917
-2,957
-4% -$4.13K 0.07% 76
2020
Q3 		$65K Buy
69,874
+10,277
+17% +$9.08K 0.05% 82
2020
Q2 		$52K Buy
+59,597
New +$52.5K 0.05% 78

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Strategic Wealth Investment Group's LCTX Position: Q2 2023 in Review

Strategic Wealth Investment Group sold out of Lineage Cell Therapeutics (LCTX) in Q2 2023, closing a stake of 31,530 shares — an estimated $47.3K sold.

Strategic Wealth Investment Group first reported a position in LCTX in Q2 2020 and held it in 12 quarters. The position peaked at $183K in Q2 2021. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2023.

  • Strategic Wealth Investment Group reported no remaining Lineage Cell Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Strategic Wealth Investment Group sold 31,530 Lineage Cell Therapeutics shares in Q2 2023, an estimated $47.3K.
  • Strategic Wealth Investment Group first reported a position in Lineage Cell Therapeutics in Q2 2020 and held it in 12 quarters.
  • Strategic Wealth Investment Group's Lineage Cell Therapeutics position peaked at $183K in Q2 2021.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2023.

Based on Strategic Wealth Investment Group's 13F filing for Q2 2023, filed 17 Jul 2023.